ArticlePloS one2025
NLRP3 inflammasome-dependent and -independent interleukin-1β release by macrophages exposed to wear and corrosion products from CoCrMo implants.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NLRP3 inflammasome activation by particles and fibers: implications for human hazard assessment.Archives of toxicology · 2026Review
- Breast Implant Illness and Autoimmune/Inflammatory Syndrome Induced by Adjuvants: Mechanistic Rationale and a Practical Multidisciplinary Diagnostic Algorithm.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wear particles and metal ions released from cobalt-chromium-molybdenum (CoCrMo) implants can trigger adverse local tissue reactions (ALTR) that can lead to implant failure. Identifying mechanisms involved in ALTR, particularly those underlying the initial inflammatory response elicited by wear particles (Cr2O3 and CoCrMo) and metal ions (Co2+ and Cr3+) is therefore critical. The macrophage pro-inflammatory response to CoCrMo particles, Co2+, and Cr3+ includes interleukin-1β (IL-1β) release, a process putatively linked to the NLPR3 inflammasome. However, the effects of Cr2O3 particles remain largely unknown. The objectives of this study were to determine whether IL-1β release by macrophages exposed to Cr2O3 particles (60 nm), CoCrMo particles (3.4 μm), Co2+, or Cr3+ is dependent on NLRP3 and caspase-1, whether NLRP3-dependent release is mediated by reactive oxygen species (ROS) and/or cathepsin B, and whether caspase-8 is involved when the release is NLRP3 independent. Bone marrow-derived macrophages (BMDM) from wild-type (wt), NLRP3-deficient (Nlrp3-/-), and caspase-1-deficient (Casp1-/-) mice were exposed to the particles or metal ions following priming with lipopolysaccharide. IL-1β release induced by Cr2O3 particles and Cr3+ was shown to be both NLRP3 and caspase-1-dependent. In contrast, IL-1β release induced by CoCrMo particles and Co2+ occurred independently of NLRP3, being caspase-1-independent in response to CoCrMo particles and partially caspase-1-dependent in response to Co2+. Further analysis suggested that NLRP3 inflammasome activation by Cr2O3 particles was cathepsin B dependent and mediated by lysosomal destabilization, whereas activation by Cr3+ was ROS-mediated. NLRP3-independent IL-1β release induced by CoCrMo particles or Co2+ was caspase-8 dependent. Collectively, these findings highlight the diversity and specificity of the mechanisms by which different CoCrMo implant wear particles and metal ions can induce IL-1β release in macrophages. Moreover, they suggest that targeting NLRP3, caspase-1, and/or caspase-8 could help mitigate the IL-1β-mediated component of the inflammatory response triggered by wear particles and metal ions from CoCrMo implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.